Why Cash Flow Value Screens Are Turning Up Japanese Large Cap Stocks

Global inflation readings are keeping central banks focused on interest rates, which keeps long term bond yields in the spotlight and makes reliable cash generation more valuable for equity investors. When money is not cheap, paying too much for growth can sting. This is where undervalued stocks based on cash flows matter. This article highlights 3 stocks from the screener that stand out on this measure.

The stocks covered below are just a starting sample, with the full screen surfacing 61 more companies with equally compelling cash flow stories that are not discussed here. To identify and analyze the ideas that best fit your style, head straight into the Undervalued Stocks Based On Cash Flows screener.

Chugai Pharmaceutical (TSE:4519)

Chugai Pharmaceutical is a Japan based drug company focused on high value treatments in oncology, autoimmune disease and rare conditions, backed by its long standing relationship with Roche. It currently generates about ¥1.34t in annual revenue, all from pharmaceuticals, and has a global footprint across Japan and overseas markets. With a market cap of roughly ¥11.4t, Chugai sits in the large cap bracket of the healthcare sector.

Investors looking at cash flow driven opportunities may find Chugai Pharmaceutical worth a closer look. The company is tightly focused on biologic drugs like Hemlibra and Actemra, which sit in areas of growing medical need, and recent guidance for 2026 plus a higher interim dividend point to management confidence in earnings quality. At the same time, reliance on a handful of flagship drugs, regulatory price pressure and a close dependence on Roche create real risk if the pipeline or partnership underperforms. Add in strong profitability metrics and fresh moves into AI supported drug discovery, and this is a business where the balance between concentration risk and high margin growth potential deserves careful attention.

Chugai Pharmaceutical’s high margin biologics and management’s 2026 guidance suggest that the real story is in the cash flows. Get the full picture, including pipeline concentration risk, in the analysis report for Chugai Pharmaceutical

Build your own cash flow shortlist

Chugai Pharmaceutical and the two other stocks in this list all came from a single Screener run, but the real value is in shaping filters that fit how you invest. Use our flexible Screener to mix cash flow, valuation, balance sheet and risk filters, or start with our curated Investing Ideas for ready made shortlists built on the same data foundation.

Recruit Holdings (TSE:6098)

Recruit Holdings is a Tokyo based HR and business solutions company that runs online job platforms, global staffing operations and lifestyle marketplaces in areas such as beauty, travel and dining. It connects job seekers and employers through HR technology and also provides temporary staffing and marketing solutions across Japan, Europe, the US and Australia. The company sits firmly in the large cap bracket with a market value of about ¥22.9t, putting it among Japan’s bigger listed stocks.

Recruit Holdings catches attention in a cash flow focused screen because it pairs HR technology platforms with a broad staffing footprint, while leaning into automation and AI to improve efficiency and service quality. For the year to March 2027, management has provided guidance with targets for revenue, operating income and EPS. Recent quarterly numbers show stronger earnings and margins alongside active share buybacks. The flip side is clear. Global labor demand remains soft, staffing revenues in key regions have weakened and management has flagged slower adoption of newer platforms in Japan, which could dampen growth if it continues. For investors, a key consideration is whether the combination of high return on equity, management guidance and cash returns to shareholders outweighs those demand and execution risks.

Recruit Holdings is pushing automation, AI and share buybacks while labor demand stays muted and platform adoption slows. See how those forces intersect in the analyst forecasts for Recruit Holdings and the one thing that could flip the story.

Murata Manufacturing (TSE:6981)

Murata Manufacturing is a global supplier of ceramic based passive components that sit inside smartphones, cars, data centers and industrial equipment, with products ranging from capacitors and inductors to sensors and communication modules. The bulk of its ¥2.03t in revenue comes from Components at about ¥1.25t, with Devices and Modules contributing roughly ¥665b and smaller contributions from other activities and internal eliminations. The company is a heavyweight in the electronics value chain with a market cap of about ¥14.99t, placing it firmly in the large cap bracket.

Murata Manufacturing appears in a cash flow focused screen because it sits at the heart of electronics supply chains while offering a mix of growth, quality and scale. Forecast earnings growth of about 24% a year and revenue growth of nearly 13% a year are combined with high quality earnings and improving profit margins, yet the stock is indicated as trading below an estimated cash flow value. The catch is a very high P/E relative to peers and a share price that has been volatile, alongside a balance sheet funded entirely by external borrowing. For investors, the key question is whether the earnings outlook and product depth across EVs, data centers and connected devices compensate for those valuation and risk considerations.

Murata Manufacturing sits at the crossroads of earnings acceleration and rich valuation, with cash flow strength that many investors may be underestimating while focusing on a high P/E and debt funded balance sheet. Get the full story in the DCF valuation analysis for Murata Manufacturing

Seeking Fresh Alternatives Beyond These Three

Fresh ideas do not stay under the radar for long. Screens are updating, momentum is building and potential breakouts can get caught fast. Move before the crowd and act now.

• Spot companies quietly building momentum before they start flying and tap into the 68 high quality undiscovered gems while they are still under the radar for now.
• Lock onto resilient businesses that can keep paying investors even when sentiment is dropping and scan the 33 dividend fortresses while those yields still look appealing.
• Track companies powering the next wave of automation and let the 37 robotics and automation stocks surface stocks riding that robotics breakout while it matters.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com